JCA Reports & Global HTA Shifts

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: Tovorafenib JCA insights, Mirvetuximab CDF implications, D-VRd NICE reversal, and Avacopan's transatlantic crisis. Let's get into it.

SaraThe Tovorafenib JCA report just dropped, and it's exposing structural tensions in rare disease HTA. The assessment flags methodological gaps in surrogate endpoint validation for pediatric oncology. Marcus, this feels like JCA pushing back on accelerated approvals without robust real-world anchors.

MarcusAgreed, but the report's silence on comparator selection is glaring. If we're to rely on progression-free survival as a primary endpoint, the control arm data needs more scrutiny. Sara, isn't this precisely where HTA bodies should demand RWE integration earlier?

SaraThat's where I disagree. JCA's focus on surrogate endpoints delays patient access. The report should acknowledge that for ultra-rare diseases, historical controls are sometimes the only feasible benchmark. Over-reliance on RWE could create more noise than signal here.

MarcusMoving to Mirvetuximab's interim CDF recommendation. The UK's Cancer Drugs Fund rejection hinges on cost-effectiveness thresholds at £30,000-£50,000 per QALY. Sara, this signals a new era for ADCs—where even targeted therapies face price compression.

SaraAbsolutely, but the real story is the CDF's operational inconsistency. The committee acknowledged unmet need yet applied standard cost-effectiveness models. Marcus, isn't this a case where value assessment frameworks need disease-specific adjustments?

MarcusPartially, but the CDF's decision reflects fiscal reality. ADC development costs are unsustainable at current price points. Sara, the burden falls on HEOR to demonstrate cost-offsets beyond drug acquisition—like reduced hospitalizations.

SaraOn D-VRd's NICE reversal, the draft guidance rejecting multiple myeloma treatment based on MRD endpoints is a watershed moment. Marcus, this proves HTA bodies remain skeptical of novel endpoints, even with strong surrogate evidence.

MarcusSkepticism is warranted. MRD as a cost-effectiveness endpoint assumes direct correlation with survival, which isn't always linear. Sara, shouldn't HTA demand longer-term RWE before accepting MRD as a decision metric?

SaraThat's too conservative. The reversal delays life-extending therapies for patients with limited options. HEOR must adapt to endpoint innovation, not anchor to outdated metrics.

MarcusFinally, Avacopan's transatlantic regulatory divergence creates a HEOR minefield. FDA approval contrasts with EMA's conditional marketing authorization. Sara, how do we reconcile these signals for global submissions?

SaraWe don't. The regulatory split forces compartmentalized evidence strategies. Marcus, this is where HEOR must bridge gaps with jurisdiction-specific value frameworks, not impose one-size-fits-all models.

MarcusCompartmentalization increases costs. Sara, the industry needs harmonized HTA pathways to avoid duplicative RWE generation. Back tomorrow on Access Brief. Show notes at outcomes-analytica.no.